EGP-437 Phase II trial to treat anterior Uveitis

[Mike Bartolatz]

Phase III Study Initiated in Patients with Anterior Uveitis
EyeGate Pharma announced in January that it has enrolled the first patient in a milestone Phase III pivotal study of its lead product EGP-437 (a late-stage asset with multiple indications for inflammatory ocular indications), for the treatment of anterior uveitis, at Tauber Eye Center in Kansas City, Mo. The randomized, double-masked, positive-controlled, noninferiority study will enroll up to 200 subjects at more than 20 U.S. sites in order to assess the effectiveness of EGP-437 in comparison to topically applied prednisolone acetate eye drops. EGP-437 will be administered using the EyeGate® II Drug Delivery System, a noninvasive iontophoretic drug delivery technology. The company's Phase II study results appear in the January 2012 issue of Ophthalmology, and reveal that approximately two-thirds of the patients reached an anterior chamber cell score of zero within 28 days, after only receiving one iontophoresis treatment. Source: Marketwire 1/5/12